In addition, the FLOWERS trial (NCT05163249) explores the efficacy and safety of osimertinib with or without savolitinib in patients with de novo MET amplified and/or c-MET overexpressed, EGFR-mutant advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.